Author: Web Desk

Explore all our news . .

Recent Posts

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies. SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage

Karachi Roads Remain in Prime Condition Despite Heavy Rainfall

Karachi: Despite receiving a substantial 227 mm of rainfall over three consecutive days, the condition of 106 roads in Karachi has remained commendably intact. The recent weather events tested the city’s infrastructure, yet no significant damages were…